Project Grant HT94252310210
Award Date
4/1/23
Completion Date
3/31/26
Dollars Obligated
$1.2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
The University of Michigan received a $925,834 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program. The grant will fund research into CDK12 as a context-specific tumorigenesis regulator and novel therapeutic target in castration-resistant prostate cancer. The research will be performed in Ann Arbor, Michigan over a three-year period from September 2021 through August 2024. Through the support of basic,...
The Regents of the University of Michigan received a $312,000.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The 2-year grant, awarded on February 1, 2024, supports research to investigate "An Unexpected Role for the Ubiquitin Proteasome System in Repeat Associated Non-AUG Translation." This basic and translational biomedical research aims to advance understanding and treatment of neurological disorders...
The University of Michigan will receive $1,169,999 under a three-year Project Grant award from the Department of the Army Medical Command to identify therapeutic vulnerabilities of bone marrow-driven recurrence of ER+ breast cancer. The award is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform military and public health care through innovative solutions for battlefield medicine and investigations into medical...
The University of Michigan will receive $702,000 under a three-year Project Grant award from the Department of the Army Medical Command to support research into new treatment strategies for ovarian cancer and PARP inhibitor-resistant tumors. The grant funding, provided through the Military Medical Research and Development program, will allow University researchers to investigate techniques for re-activating Protein Phosphatase 2A (PP2A) as a potential means of treating homologous recombination...
The University of Michigan will receive $782,729 from the Department of the Army Medical Command under a Project Grant award through the Military Medical Research and Development program (CFDA 12.420) to improve outcomes for women with ovarian cancer. The four-year award beginning September 1, 2022 will support research to transform healthcare for Service Members and the public through innovative medical solutions for the battlefield and investigation of solutions for ovarian cancer. The...
This $1,248,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will support the "RARE-CANCER COMMONS: A HUB FOR ACCELERATING INDIVIDUALIZED RARE CANCER THERAPY THROUGH INTEGRATION OF SINGLE-CELL AND CLINICAL GENOMICS DATA" research initiative at the University of Michigan. The project, running from November 1, 2024 to October 31, 2027, will leverage the University's extensive research capabilities to...
The University of Michigan will receive $304,472 over two years through a Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program. The grant will fund research into regulating prostate skeletal bone metastases through TIM-3-dependent efferocytosis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care through innovative and...
This $1,404,000.00 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program to the Regents of the University of Michigan, Office of Research and Sponsored Projects (doing business as the University of Michigan) on September 1, 2023. The funding will support research to target the lipid kinase PIKfyve in neuroendocrine prostate cancer over a 3-year period ending on August 31, 2026. The University of Michigan is a leading U.S....
This Cooperative Agreement award of $1,248,000.00 from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports the "UNIVERSITY OF MICHIGAN PHASE 1/2 CLINICAL TRIALS ASSESSMENT IN KIDNEY CANCER THERAPEUTICS (U-MPAKT)" project at the University of Michigan. The award period runs from September 15, 2024 to September 14, 2028. The funding will enable the University of Michigan to conduct Phase 1 and Phase 2 clinical trials to assess...
The Department of the Army Medical Command awarded a $1,100,747 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Regents of the University of Michigan. The grant, awarded on April 1, 2025, supports research to engineer antibody-drug conjugates that can coordinate the innate and adaptive immune systems for curative responses. The University of Michigan, a leading public research institution, will leverage its expertise in protein engineering,...